Tesh Khullar Discusses the Emerging Role of Biosimilars in Oncology

Tesh Khullar, senior vice president & advisor, Flatiron Health, discusses the first to anticancer biosimilars having recently entered the market.

Tesh Khullar, senior vice president & advisor, Flatiron Health, discusses the first to anticancer biosimilars having recently entered the market.

Transcript

With the first 2 anticancer biosimilars having recently entered the market and more waiting to enter, do you think biosimilars will start to play a bigger role in oncology?

I think absolutely. They already have. What we’re seeing on the biosimilar front is actually a greater adoption than most folks thought initially for the non-supportive chemotherapy agents like Avastin, Herceptin, Rituxan. We were thinking maybe a 10% adoption right away. It’s looking more like it’s 15% to 20%. So, I think you’re going to see that trend continue. Biosimilars are going to be here to stay in my opinion and it’s going to be a great opportunity for community oncology.

Related Videos
Screenshot of Eleonora Lad, MD, PhD, smiling
Davey B. Daniel, MD, Chief Medical Officer, OneOncology
Debra Patt, MD, PhD, MBA, Executive Vice President, Texas Oncology
Michael Burger
Jeffrey Casberg
Amy Valley, Vice President for Clinical Strategy and Technology Solutions, Cardinal Health
Ben Jones, Vice President of Government Relations and Public Policy, US Oncology Network
Yuqian Liu, PharmD
Screenshot of Adam Colborn, JD
Related Content
© 2023 MJH Life Sciences
AJMC®
All rights reserved.